LaiMang Bio
莱芒生物
LaiMang Bio (莱芒生物) is a Shenzhen-based biotech company developing novel tumor immunotherapy drugs through a platform that combines immune metabolic reprogramming with artificial intelligence . The company raised nearly RMB 100 million in its angel round in January 2022, led by Tiantu Capital with follow-on from 5Y Capital and XtalPi , and subsequently closed RMB 50 million in additional angel+ and angel++ rounds in mid-2024, with Tiantu Capital and XtalPi both increasing their stakes . In July 2023, LaiMang entered a comprehensive strategic partnership with Xiangxue Life Sciences .
AI-generated — may contain errors, please verify.
Coverage
Confidence Is Tomorrow's Trailblazer | 5Y News Monthly
The major events that happened last month.
五源资本·5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
五源资本·July: The Courage to Keep Believing | 5Y News Monthly
The big news from last month.
五源资本·June, the World's Childhood | 5Y News Monthly
The big news from last month.
五源资本·February: When the Tiger Roars, the Wind Rises | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Limmuno Biotech Closes Nearly RMB 100 Million Angel Round
Immunometabolic Reprogramming + AI-Powered Computation for Innovative Cancer Immunotherapy
五源资本·
